Centerbridge or Oaktree, as applicable, beneficially own less than 60% but at least 40% of their respective Initial Investor Interest, then they will each have the right to designate at least two
directors to the Board. If Centerbridge or Oaktree, as applicable, beneficially own less than 40% but at least 20% of their respective Initial Investor Interest, then they will each have the right to designate at least one director to the Board. If
Centerbridge or Oaktree, as applicable, cease to own at least 20% of their respective Initial Investor Interest, then they will have no right to designate any directors to the Board.
Pursuant to the Investor Rights Agreement, the Additional Investors will have a continuing right to designate one director for election to the
Board, subject to its (and permitted transferees) beneficial ownership of at least 60% of their Initial Investor Interest. If the Additional Investors beneficially own less than 60% of their Initial Investor Interest, then they will have no
right to designate any directors to the Board. The designee of the Additional Investors shall be the person nominated, separately and not jointly, by those Additional Investors holding at least 65% of the shares of Series A Preferred Stock held by
the Additional Investors at such time. After the Additional Investors no longer have a right to designate a director as described above, if the Company becomes aware that at least 20% of the Series A Preferred Stock issued as of the Effective Date
is held by stockholders other than Centerbridge and Oaktree, then the holders of a majority of the Series A Preferred Stock then outstanding (excluding Series A Preferred Stock held by Centerbridge and the Oaktree) will collectively have the right
to designate one director to the Board.
Series B Preferred Stock Certificate of Designations
On the Effective Date, we issued 834,800,000 shares of mandatorily redeemable series B preferred stock (the Series B Preferred
Stock) to Honeywell in satisfaction and discharge of certain claims of Honeywell. Pursuant to the Certificate of Designations for the Series B Preferred Stock, Honeywell had the right to elect or appoint one director to our Board until the
first date on which certain amounts due to Honeywell under the terms of the Series B Preferred Stock were, on aggregate, equal to or less than $125.0 million.
Under the terms of the original Certificate of Designations for our Series B Preferred Stock, we were obligated to redeem an aggregate number
of shares of Series B Preferred Stock equal to an aggregate redemption amount of $834.8 million, payable to Honeywell in annual cash installments beginning in 2022 and ending in 2030, subject to various conditions and put and call rights set
forth in the Certificate of Designations for the Series B Preferred Stock. On December 28, 2021, we elected to complete an early partial redemption of 345,988,497 shares of Series B Preferred Stock for an aggregate price of approximately
$211 million, on February 18, 2022, we elected to complete an early partial redemption of 217,183,244 shares of Series B Preferred Stock for an aggregate price of approximately $197 million, and on June 28, 2022, we elected to
complete a final early partial redemption of the remaining 271,628,259 shares of Series B Preferred Stock for an aggregate price of approximately $212 million. Following the completion of the full redemption of the Series B Preferred Stock,
Honeywell ceased to have the right to nominate a director to the Board.
Consultant Fee Letter
On April 26, 2021, we entered into a Consultant Fee Reimbursement Letter with Oaktree and its consultant (the Fee
Letter). The Fee Letter was executed in order to document our agreement to (a) reimburse, pursuant to the PSA, Oaktrees reasonable and documented fees and expenses incurred in its retention of the consultant in connection with
the transactions contemplated by the PSA up to $112,500 and (b) facilitate Oaktrees arrangements with the consultant to provide a co-investment opportunity in shares of Series A Preferred Stock with
an aggregate subscription price of approximately $250,000, which Oaktree otherwise would have been entitled to acquire pursuant to the PSA.
Capital Transformation Transactions
On April 13, 2023, we announced that we had entered into separate transaction agreements with the Centerbridge Investors and the Oaktree
Investors to effect a series of integrated transactions designed to increase the attractiveness of the Company to investors, including by simplifying our capital structure through a conversion of all shares of the Series A Preferred Stock into
shares of Common Stock on or about July 3, 2023.
The transactions contemplated by the transaction agreements (collectively, the
Transaction Agreements) were determined to be fair to and in the best interests of the Company and the holders of the Companys Common Stock by an independent committee consisting of members of the Board who are disinterested
with respect to the Series A Preferred Stock (the Preferred Conversion Committee), and by the full Board.
Series A
Repurchases
Pursuant to the Transaction Agreements, we have agreed to repurchase approximately $570 million of shares of Series
A Preferred Stock from the Centerbridge Investors and the Oaktree Investors, including approximately $280 million of shares from the Centerbridge Investors and approximately $290 million of shares from the Oaktree Investors (together, the
Series A Repurchases). We will pay to the Centerbridge Investors and the Oaktree Investors a cash price of $8.10 per repurchased share, which amount will be adjusted to equal the volume-weighted average price of the Common Stock
for the fifteen trading days following the announcement of the transactions, which was April 13, 2023, subject to a minimum price of $7.875 and a maximum price of $8.50 (the Investor Purchase Price).
As holders of Series A Preferred Stock, the Centerbridge Investors and the Oaktree Investors will receive the dividends and other amounts
payable as described in Second Amended and Restated Certificate of Designations; Conversion below. In addition, pursuant to the Transaction Agreements, at the closing of the Series A Repurchases, the Centerbridge Investors and the
Oaktree Investors will also be entitled to receive, for each repurchased share, an amount equal to any dividends or other amounts paid or payable on the shares of Series A Preferred Stock from the closing of the Series A Repurchases through the
Conversion (as defined below), in the same type of consideration as will be paid to all other holders of Series A Preferred Stock.
Second Amended and Restated Certificate of Designations; Conversion
To effect the conversion into shares of Common Stock of all shares of Series A Preferred Stock that are not repurchased, the Board has
approved an amendment and restatement to the current Certificate of Designations for the Series A Preferred Stock (as so amended and restated, the Second Amended and Restated Certificate of Designations). Pursuant to the
Transaction Agreements, the Centerbridge Investors and the Oaktree Investors have each delivered to the Company an irrevocable written consent approving and adopting the Second Amended and Restated Certificate of Designations. Accordingly, the
effectiveness of the Second Amended and Restated Certificate of Designations is subject only to the satisfaction of the conditions in the Transaction Agreements, the filing with the SEC and dissemination to holders of Series A Preferred Stock of an
Information Statement on Schedule 14C and a notice of action by written consent, and the filing of the Second Amended and Restated Certificate of Designations with the Secretary of State of the State of Delaware.
After the effectiveness of the Second Amended and Restated Certificate of Designations until September 30, 2023, the Second Amended and
Restated Certificate of Designations suspends the potential occurrence of an Automatic Conversion Event (as defined therein) and requires us to cause a conversion of all shares of Series A Preferred Stock into shares of Common
Stock if the Series A Repurchases have been completed (the Conversion). Upon the Conversion, each holder of Series A Preferred Stock as of the Conversion will receive one (1) share of Common Stock for each share of Series A
Preferred Stock then held. The Conversion will occur on or after the third (3rd) trading day after the Company provides written notice of the Conversion to the holders of the Series A Preferred
Stock.
In addition, upon the Conversion, each holder of Series A Preferred Stock will also receive an amount equal to the amount of
accrued and unpaid dividends on the Series A Preferred Stock plus an additional amount that represents the dividends on the Series A Preferred Stock that would have accrued through September 30, 2023 (collectively, the 2023 Conversion
Additional Payment Amount). The 2023 Conversion Additional Payment Amount may be paid in cash or a combination of cash and shares of Common Stock, except that at least $0.144375 of the 2023 Conversion Additional Payment Amount paid per
share of Series A Preferred Stock must be paid in cash. Any shares of Common Stock issued in payment of the 2023 Conversion Additional Payment Amount will be valued at the Investor Purchase Price. The 2023 Conversion Additional Payment Amount will
be paid within ten (10) business days following the Conversion.
As a result, holders of Series A Preferred Stock will receive
dividends or amounts payable in respect of their shares of Series A Preferred Stock until Conversion equal to:
|
|
|
$0.17 per share, representing the preference dividends that will accrue on the Series A preferred Stock from
April 1, 2023 through June 30, 2023; plus |
|
|
|
Approximately $0.6835 per share, representing other accrued and unpaid preference dividends on the Series A
Preferred Stock; plus |
|
|
|
$0.144375 per share, representing the preference dividends that would have accrued on the Series A Preferred
Stock from July 1, 2023 through September 30, 2023. |
If the Series A Repurchases have not been completed by
September 30, 2023, the provisions of the Second Amended and Restated Certificate of Designations relating to the Conversion will cease to have any effect, and the Automatic Conversion Event trigger event will be restored as if no
amendment to the Certificate of Designations for the Series A Preferred Stock had occurred.
In accordance with the Transaction
Agreements, the Company has agreed to promptly take such actions as are necessary or advisable to make the Second Amended and Restated Certificate of Designations effective, including the filing and dissemination of a definitive Information
Statement on Schedule 14C with the SEC and the dissemination to holders of the Series A Preferred Stock a notice of action by written consent with respect to the adoption and approval of the Second Amended and Restated Certificate of Designations.
Debt Financing
In
order to fund the Series A Repurchases and the other transactions contemplated by the Transaction Agreements, we have agreed to use our commercially reasonable efforts to complete a debt financing (the Debt Financing) in the
amount of $700 million, subject to reduction of up to 5% if the Preferred Conversion Committee determines in good faith that such reduction is in the best interests of the Company (as so reduced, the Requisite Financing
Amount), on terms and conditions satisfactory to the Preferred Conversion Committee in its reasonable discretion. We currently intend to complete the Debt Financing by amending our Credit Agreement, to provide for (i) a new Series B
term loan in the amount of the Requisite Financing Amount, (ii) an amendment to the definition of a Restricted Payment to permit the payments contemplated by the Transaction Agreements, and (iii) any other changes that are
necessary or advisable to effect the transactions contemplated by the Transaction Agreements. We intend to incur the indebtedness under the Debt Financing prior to the completion of the Series A Repurchases.
Investor Rights and Limitations
Pursuant to the Investor Rights Agreement, the Centerbridge Investors and the Oaktree Investors currently has the right to designate up to
three (3) members for election to the Board, based on their ownership of the Companys equity securities. Pursuant to the Transaction Agreements, the Centerbridge Investors and the Oaktree Investors have each agreed to limit its existing
board designation rights to one (1) designee. Furthermore, this number will be reduced to zero (0) for the Centerbridge Investors, on the one hand, and the Oaktree Investors, on the other hand, at such time as it and its affiliates
beneficially own less than 10% of the outstanding shares of voting securities of the Company on an as-converted basis.
From the date of the Transaction Agreements, the Centerbridge Investors and the Oaktree Investors and their respective controlled affiliates
is subject to certain limitations on their investor rights, which include, among other things, an agreement (i) not to acquire beneficial ownership of additional shares of the Companys equity securities if it would result in the
Centerbridge Investors or the Oaktree Investors, as applicable, together with its respective controlled affiliates, beneficially owning more than 15% of the outstanding voting securities of the Company on an
as-converted basis, and (ii) to vote any shares held in excess of 18% in the manner voted by holders who beneficially own less than 18% of the Companys voting securities. These limitations will
terminate on the earliest to occur of (i) eighteen months from the date of the Transaction Agreements, (ii) the commencement of an unsolicited tender offer for a majority of the voting securities of the Company, or (iii) any
insolvency or bankruptcy of the Company.
Lock-Up
Pursuant to the Transaction Agreements, the Centerbridge Investors and the Oaktree Investors have each agreed to lock-up provisions with respect to the shares of the Companys equity securities that they and their affiliates beneficially own. The lock-up provisions restrict the
Centerbridge Investors and the Oaktree Investors from (i) directly or indirectly transferring or disposing of any of their shares, (ii) entering into certain transactions that transfer or dispose of their economic or other interests in
such shares, or (iii) publicly disclosing any intention to do either of the foregoing. The lock-up restrictions will be released with respect to 50% of the shares beneficially owned by the Centerbridge
Investors and the Oaktree Investors and its respective affiliates on the date that is six (6) months from the earlier to occur of (x) the completion of the Series A Repurchases and (y) 45 days from the execution of the Transaction
Agreements (the Lock-Up Trigger Date), and with respect to all of the shares beneficially owned by the Centerbridge Investors and the Oaktree Investors and its respective affiliates on the
date that is twelve (12) months from the Lock-Up Trigger Date. The lock-up restrictions are subject to exceptions, including transfers made with the prior written
consent of the Company and the approval of the Preferred Conversion Committee, as well as customary exceptions for transfers in connections with tender offers, certain other fundamental transactions, and the grant of proxies in connection with
annual or special meetings of the Company.
Share Repurchase Program
The Board has announced an increase in our share repurchase program, to an aggregate amount of $250 million (the Share
Repurchase Program). Pursuant to the Share Repurchase Program, we may purchase shares of Series A Preferred Stock or Common Stock on a discretionary basis in open market transactions, privately negotiated purchases and other transactions
from time to time, on terms satisfactory to the Preferred Conversion Committee in its reasonable discretion. The Share Repurchase Program retains its prior expiration date of November 15, 2023, but may be extended, earlier terminated or
modified by the Board at any time. Pursuant to the Transaction Agreements, neither the Centerbridge Investors nor the Oaktree Investors may sell or tender securities that are subject to the lock-up provisions
described above in any transaction that is part of the Share Repurchase Program without the prior written consent of the Preferred Conversion Committee.
Additional Terms and Conditions
The Transaction Agreements contain customary representations and warranties of the Company and the Centerbridge Investors and the Oaktree
Investors. The closing of each Series A Repurchase under the Transaction Agreements is subject to completion of the Debt Financing on terms and conditions satisfactory to the Preferred Conversion Committee in its reasonable discretion, the
effectiveness of the Second Amended and Restated Certificate of Designations, the substantially concurrent closing of the other Series A Repurchase and other customary closing conditions. Pursuant to the Second Amended and Restated Certificate of
Designations and as described above, the Conversion is conditioned upon the closing of the Series A Repurchases.
In the twelve
(12) months following the date of the Transaction Agreements, if we amend, waive or grant any consent under the Transaction Agreement with the Centerbridge Investors, on the one hand, or the Transaction Agreement with the Oaktree Investors, on
the other, we will offer the same amendment, waiver or consent to the Oaktree Investors or the Centerbridge Investors, respectively. The Transaction Agreements may be terminated in certain circumstances by each of the Company (with the prior
approval of the Preferred Conversion Committee) and by the Centerbridge Investors and the Oaktree Investors, including if the Series A Repurchases have not occurred by September 15, 2023.
23